Caredx Stock Price, News & Analysis

CareDx, Inc. (CDNA) will present its AlloSeq portfolio at the EFI 2022 Conference from May 17-20 in Amsterdam. The AlloSeq solutions, crucial for HLA typing and post-transplant monitoring, highlight the company's leadership in transplant diagnostics. CEO Reg Seeto emphasized CareDx's unique focus on transplant solutions, which serve as vital tools for researchers and clinicians. The symposium on May 18 will discuss advancements in patient care related to transplantation, showcasing significant collaborations in the field.

CareDx, Inc. (CDNA) reported an 18% year-over-year revenue increase to $79.4 million for Q1 2022, driven by strong performance in testing services, which generated $66.4 million. The company showcased scientific leadership at the International Society of Heart and Lung Transplantation with over 25 presentations and secured $44.9 million in damages against Natera for false claims. Despite revenue growth, CareDx recorded a net loss of $19.6 million and a negative EBITDA of $5.6 million. The company reiterated its full-year 2022 revenue guidance of $330 million to $350 million.

CareDx, Inc. (CDNA) announced new data from the multi-center OKRA study confirming that AlloMap Kidney can predict allograft rejection, specifically antibody-mediated rejection (ABMR) and T cell-mediated rejection (TCMR). With a negative predictive value of 95%, this gene expression profiling can effectively distinguish rejection from quiescence in kidney transplant patients. CEO Reg Seeto noted that these findings advance their KidneyCare solutions. This data aligns with previous studies indicating AlloSure's effectiveness in monitoring renal transplant rejection.

CareDx, Inc. (CDNA) announced that Board member Dr. Hannah Valantine received the 2022 Lifetime Achievement Award from the International Society for Heart and Lung Transplantation during their annual meeting in Boston. Valantine's contributions include pioneering research in heart transplantation and innovations like AlloMap® Heart. Her leadership in the field and efforts to promote health equity in transplantation are highlighted. CEO Reg Seeto praised her for shaping public policy and improving patient care in transplant medicine.

CareDx, Inc. (Nasdaq: CDNA) has announced an expansion to its HeartCare multimodality portfolio, adding an AI prognostic tool for cardiac allograft vasculopathy (CAV) in partnership with OrganX. This development aims to enhance patient stratification by assessing the risk of CAV, a significant cause of heart transplant failure. By integrating this AI tool with existing products like AlloMap® and AlloSure®, CareDx intends to offer a more personalized approach to interventions for improving long-term heart transplant outcomes. The initiative follows positive outcomes from previous AI applications in the KidneyCare portfolio.

CareDx, Inc. (Nasdaq: CDNA) will report its first-quarter 2022 financial results after market close on May 5, 2022. Following the report, company management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET. Interested participants can join by calling 877-300-8521 for domestic or 412-317-6026 for international access, using Conference ID: 10165254. CareDx specializes in precision medicine solutions for transplant patients, with offerings that include diagnostic testing and digital healthcare solutions.

CareDx, Inc. (Nasdaq: CDNA) announced that CEO Reg Seeto has been appointed Corporate Chair of the ISHLT Foundation's Global Steering Committee. This committee aims to advance innovations in heart and lung transplantation through the "Fostering Excellence Campaign," which will fund vital research and career development awards. CareDx aims to improve outcomes for patients with advanced heart and lung disease, aligning with the ISHLT Foundation's mission. This collaboration highlights CareDx's commitment to enhancing transplant patient care.

CareDx announces the validation of its OTTR Patient Management Software for SMART on FHIR standards, enhancing interoperability in healthcare. This announcement aligns with their presentation of new data on AlloHeme and AlloCell during the Tandem Meetings from April 23-26, 2022, in Salt Lake City, Utah. These innovations are aimed at improving patient monitoring for allogeneic hematopoietic stem cell transplants and therapies. The ACROBAT study will further evaluate AlloHeme's ability in disease relapse detection, promising advancements in patient care.

CareDx, Inc. (Nasdaq: CDNA) announced its collaboration with UC Davis Health to launch a new program named Pluralist. This initiative focuses on improving organ donation and transplantation awareness in underserved communities in California. Through digital education and community engagement, the program aims to address health disparities and increase organ donations, particularly among minority populations who represent a significant share of transplant recipients. CareDx’s contribution to this project underscores its commitment to health equity in transplantation.